ライフサイエンスコーパス: loop diuretic

1 and treatment with an antiarrythmics drug or loop diuretic).

2 tion rate and were more often treated with a loop diuretic.

3 urinary sodium when used in combination with loop diuretic.

4 ion fraction <35%, and use of eplerenone and loop diuretic.

5 ulation of blood pressure, and response to a loop diuretic.

6 level and are pharmacologically inhibited by loop diuretics.

7 iabetes mellitus and 96 (60%) were receiving loop diuretics.

8 adults with cardiovascular disease or taking loop diuretics.

9 andard decongestive treatments that included loop diuretics.

10 evidence of treatment effect modification by loop diuretics.

11 eart failure recorded but were not receiving loop diuretics.

12 and prevent congestion has historically been loop diuretics.

13 de or matching placebo on top of intravenous loop diuretics.

14 de or matching placebo on top of intravenous loop diuretics.

15 he molecular mechanisms of its inhibition by loop diuretics.

16 was stratified according to previous use of loop diuretics.

17 a novel approach to potentiate the action of loop diuretics.

18 effect of empagliflozin in combination with loop diuretics.

19 ailure management, typically addressed using loop diuretics.

20 fluid overload despite significant doses of loop diuretics.

21 inical outcomes than those not discharged on loop diuretics.

22 it is the target of the clinically important loop diuretics.

23 sts (0.69 [0.50-0.96], 0.48 [0.35-0.66]), or loop diuretics (0.67 [0.53-0.85], 0.45 [0.37-0.55]).

24 >/=2 QT-prolonging drugs (2.6 [1.9-5.6]), or loop diuretic (1.4 [1.0-2.0]), age >68 years (1.3 [1.0-1

25 y higher for heart failure in the absence of loop diuretics [22%; adjHR 1.2 (95% CI 1.1-1.3)], substa

26 ection fraction of <40% (7.7%), or were on a loop diuretic (29.9%).

27 etic Resistance cohort receiving intravenous loop diuretics (462 administrations in 285 patients) und

28 , and highest for heart failure treated with loop diuretics [52%; adjHR 2.2 (95% CI 2.0-2.2)].

29 s on loop diuretics compared to those not on loop diuretics (adjusted mean difference vs. placebo: +9

30 line characteristics, cumulative in-hospital loop diuretic administered, and worsening of renal funct

31 sodium handling, to assess sodium exit after loop diuretic administration and FENa to assess the net

32 sing a spot urine sample collected 2 h after loop diuretic administration.

33 pot urine sample obtained 1 or 2 hours after loop diuretic administration.

34 Evaluating 638 loop diuretic administrations, the NRPE showed excellent

35 slocation rate, apparent ion affinities, and loop diuretic affinity, consistent with a proposed role

36 re likely to be treated with high doses of a loop diuretic agent as an outpatient (all p < 0.001).

37 eart Association class at randomization, and loop diuretic agent before hospitalization.

38 iltration rate, and fewer new initiations of loop diuretic agent therapy.

39 ie, adding a second-line diuretic agent to a loop diuretic agent, should be reserved for those patien

40 mally acting agents (e.g., acetazolamide and loop diuretic agents) are preferred.

41 mptoms and congestion can be controlled with loop diuretic agents, the main focus should be rapid gui

42 ts as much as possible with diuretic agents (loop diuretic agents, thiazides, acetazolamide) or mecha

43 ved for those patients who do not respond to loop diuretic agents.

44 ) and 6.6% (144 of 2,191) of patients in the loop diuretic and no loop diuretic groups, respectively

45 dy was to determine the relationship between loop diuretics and clinical outcomes in patients with HF

46 in 5,864 subjects; of these, 5,320 received loop diuretics and had dose data recorded.

47 eceptor antagonist, enhances the response to loop diuretics and may have a renal protective effect.

48 Second-line therapeutic options include loop diuretics and salt tablets, urea, and V2 receptor a

49 gets of clinically important drugs including loop diuretics and their disruption has been implicated

50 or more, and 2 doses or more of intravenous loop diuretics and/or new hemodialysis or continuous kid

51 re on no diuretic, 769 (12.3%) were on a non-loop diuretic, and 4811 (76.8%) were on a loop diuretic

52 Association Class III or IV, nearly all on a loop diuretic, and 70% with a HF hospitalization in the

53 n angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin.

54 in the following subgroups: no diuretic, non-loop diuretic, and loop diuretic furosemide equivalent d

55 844 (4%) had heart failure recorded and took loop diuretics, and 5156 (3%) had heart failure recorded

56 ricosuric, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and

57 Hypersensitivity to thiazide and loop diuretics, angiotensin-converting enzyme inhibitors

58 Loop diuretics are a primary therapy for the symptomatic

59 Loop diuretics are an essential component of therapy for

60 Loop diuretics are commonly used to control congestive s

61 for the management of hypertension, whereas loop diuretics are often needed for volume overload, whi

62 Loop diuretics are one of the cornerstones of treatments

63 Intravenous loop diuretics are the mainstay of therapy for patients

64 Loop diuretics are used for congestion relief, and dose

65 th are its cardinal manifestations for which loop diuretics are used.

66 r type 2 inhibitors, exercise, HF self-care, loop diuretics as needed to maintain euvolemia, and weig

67 o eplerenone would lead clinicians to reduce loop diuretics, as a consequence of the improvement in p

68 ggest a role for neurohormonal activation in loop diuretic-associated mortality.

69 on-loop diuretic, and 4811 (76.8%) were on a loop diuretic at baseline.

70 cker Evaluation of Survival Trial) receiving loop diuretics at baseline were analyzed (N = 2,456).

71 pronounced benefits among patients receiving loop diuretics at baseline.

72 achieved despite a lower mean daily dose of loop diuretics at day 90 in the HIC arm.

73 7,936 patients, 5,568 (70%) were prescribed loop diuretics at discharge.

74 luded: (1) observational: patients receiving loop diuretics at the Yale Transitional Care Center (N=1

75 nts with HF (n=128) receiving treatment with loop diuretics at the Yale Transitional Care Center.

76 or placebo added to standardized intravenous loop diuretics (at a dose equivalent to twice the oral m

77 and VIP+ neurons-a low concentration of the loop diuretic bumetanide had differential effects on AVP

78 sses, and pharmacologic inhibition using the loop diuretic bumetanide inhibits in vitro Transwell mig

79 Since NKCC2 is the molecular target of the loop diuretics bumetanide and furosemide, we asked about

80 Preclinical data suggest that the loop-diuretic bumetanide might be an effective treatment

81 hNKCC1), both in the absence and presence of loop diuretic (bumetanide or furosemide), using single-p

82 (reference group), 23 963 (12%) were taking loop diuretics but had no heart failure recorded, 7844 (

83 nhibitors will likely be coprescribed with a loop diuretic, but this combined effect is not well-defi

84 Dapagliflozin reduced new initiation of loop diuretics by 32% [hazard ratio (HR) 0.68; 95% confi

85 Binding of loop diuretics can curtail their action in the loop of H

86 score improvement was greater in patients on loop diuretics compared to those not on loop diuretics (

87 d a longer median time to the second dose of loop diuretics compared with long call patients (17.9 ho

88 Rodents chronically administered loop diuretics develop DR due to compensatory distal tub

89 te medication data and who were prescribed a loop diuretic, diuretic dose increase was defined as: (1

90 se the formation of mineralized nodules, but loop diuretics do not.

91 ntion strategies (atrial natriuretic factor, loop diuretics, dopamine, mannitol) have shown no clear

92 Loop diuretic dose (furosemide equivalent) was 80 (40, 1

93 etic use categories (Pinteraction = 0.64) or loop diuretic dose (Pinteraction = 0.57).

94 weight loss (WL), WL adjusted for mean daily loop diuretic dose (WL-adjusted), area under the curve o

95 rics of disease severity such as higher home loop diuretic dose and NT-proBNP (N-terminal pro-B-type

96 -9.1, -4.7] from no diuretics to the highest loop diuretic dose category; interaction P = .39).

97 From baseline to 52 weeks, loop diuretic dose decreased by 17% in the semaglutide g

98 First sustained loop diuretic dose increases were less frequent, and sus

99 placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67 [95%

100 Eplerenone treatment led to a loop diuretic dose reduction during follow-up without ev

101 ity and mortality regardless of the baseline loop diuretic dose used: hazard ratio for the outcome of

102 tion (NRPE) predicts natriuresis following a loop diuretic dose using a urine sample 2 h after the do

103 d as cumulative weight change per cumulative loop diuretic dose, was compared across treatment assign

104 -hour urine volume, and percentage change in loop diuretic dose.

105 g placebo on top of standardized intravenous loop diuretics (dose equivalent of twice oral maintenanc

106 Dapagliflozin was associated with reduced loop diuretic doses (560 mg [Q1-Q3: 260-1,150 mg] vs 800

107 y hemoconcentration had higher average daily loop diuretic doses (p = 0.001), greater weight loss (p

108 eatment was associated with lower prescribed loop diuretic doses throughout the follow-up; lower dose

109 Both baseline and follow-up incremental loop diuretic doses were associated with worse prognosis

110 Loop diuretic doses were on averaged doubled during the

111 symptoms, which enables clinicians to reduce loop diuretic doses.

112 VR 0.81, 95% CI 0.76-0.86, p<0.0001) and non-loop diuretic drugs (0.87, 0.79-0.96, p=0.007), and incr

113 osemide, consistent with the hypothesis that loop diuretic drugs bind within the translocation cavity

114 e in pulmonary congestion (lung ultrasound), loop diuretic efficiency (weight change per 40 mg of fur

115 ion, cumulative urine and sodium output, and loop diuretic efficiency [P 0.33 for all]) or neurohormo

116 Loop diuretic efficiency was less with dapagliflozin tha

117 Using propensity scores for receipt of loop diuretics estimated for each of the 7,936 patients,

118 Participants received their home oral loop diuretic followed by a supervised timed urine colle

119 thy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepator

120 bgroups: no diuretic, non-loop diuretic, and loop diuretic furosemide equivalent doses of <40, 40, an

121 me, a disease that mimics the effects of the loop diuretic furosemide, ClC-Kb/K2 is assumed to have a

122 ypotonic conditions, and is inhibited by the loop diuretic furosemide.

123 e of this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic aci

124 ), both in the absence and presence of bound loop diuretic (furosemide or bumetanide).

125 includes escalation or trial of intravenous loop diuretics (furosemide or bumetanide) in bolus (2-3

126 ears (HR: 1.05, 95% CI: 0.51 to 2.17), daily loop diuretic, furosemide equivalents >240 mg (HR: 1.49,

127 Treatment with a loop diuretic, furosemide, under insulinopenic condition

128 Patients in the loop diuretic group had a significantly lower risk of 30

129 191) of patients in the loop diuretic and no loop diuretic groups, respectively (HR when the use of l

130 on who received a discharge prescription for loop diuretics had significantly better 30-day clinical

131 cute decompensated heart failure (ADHF), and loop diuretics have historically been the cornerstone of

132 Loop diuretics have well-described toxicities, and loss

133 utcomes associated with the use of high-dose loop diuretics (HDLD).

134 diuretic (HR 1.44 [95% CI 1.00, 2.10]), or a loop diuretic (HR 2.31 [95% CI 1.36, 3.91]) was associat

135 netic ablation of claudin-14 or the use of a loop diuretic in mice abrogated HDAC inhibitor-induced h

136 lthough furosemide is the most commonly used loop diuretic in patients with heart failure, some studi

137 diuretics are considered less effective than loop diuretics in CKD.

138 The demonstrated efficacy of loop diuretics in managing congestion is balanced by the

139 Effective diuretic regimens using loop diuretics in patients with acute decompensated hear

140 When added to treatment with loop diuretics in patients with acute decompensated HF,

141 gs of our study demonstrate increased use of loop diuretics in patients with BP before the developmen

142 Response to loop diuretics in patients with nephrotic syndrome (NS)

143 regulate osmotic stability are disrupted by loop diuretics in rats.

144 transporters are inhibited by the so-called loop diuretics including bumetanide, and these drugs are

145 Loop diuretics, including furosemide, bumetanide, and to

146 The mean dose of loop diuretic increased over time in the placebo arm, a

147 ot analysis of NCC protein demonstrated that loop diuretics increased NCC protein abundance by nearly

148 d timed 6-hour urine collections to quantify loop diuretic-induced cumulative sodium output.

149 se is magnified in patients with baseline or loop diuretic-induced elevated HCO3 (marker of proximal

150 uretic sodium reabsorption (CPDSR) following loop diuretic-induced natriuresis, minimizing sodium exc

151 e that increased NCC activity during chronic loop diuretic infusion is associated with increases in N

152 designed to test the hypotheses that chronic loop diuretic infusion, with replacement of NaCl losses,

153 es for TM3 residues in ion translocation and loop diuretic inhibition.

154 utpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple t

155 Chronic infusion of loop diuretics into animals induces structural and funct

156 Coadministration of BNP and loop diuretic is effective in maximizing natriuresis and

157 is concluded that urinary protein binding of loop diuretics is not a major mechanism for the diuretic

158 When administration of moderate doses of loop diuretics is not sufficient, patients can be treate

159 Furosemide, a loop diuretic, is commonly used in patients with congest

160 g hemoconcentration received higher doses of loop diuretics, lost more weight/fluid, and had greater

161 220), non-loop diuretic only (n = 223), and loop diuretic [<40 (n = 219), 40 (n = 309), and >40 (n =

162 There was no difference in mean loop diuretic management (daily furosemide equivalents)

163 over time and appeared to be independent of loop diuretic management.

164 e, administration of mixtures of albumin and loop diuretics may enhance responses.

165 nd tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4]

166 ted in two HF patient cohorts receiving oral loop diuretics: Mechanisms of Diuretic Resistance (MDR)

167 events the drop in chloride levels caused by loop diuretic monotherapy.

168 ears; 55% women), 161 935 (81%) neither took loop diuretics nor had a diagnostic record of heart fail

169 baseline, across no diuretic (n = 220), non-loop diuretic only (n = 223), and loop diuretic [<40 (n

170 A loop diuretic only strategy was associated with an incre

171 ed decongestive response in the placebo arm (loop diuretics only), both with regard to reaching the p

172 cs: heart failure on problem list, inpatient loop diuretic, or brain natriuretic peptide level of 500

173 Loop diuretics other than furosemide were converted to f

174 reabsorption, can improve the efficiency of loop diuretics, potentially leading to more and faster d

175 ys between first HF hospitalization or first loop diuretic prescription and ATTR-CM diagnosis.

176 For the 1,882 veterans with a loop diuretic prescription before ATTR-CM diagnosis, the

177 nsional setting identified patients with >=2 loop diuretic prescriptions (aRD, -2.6%, 95% CI, -5.0% t

178 ation of the use of a nonrenally metabolized loop diuretic rather than furosemide.

179 n can increase the volume of distribution of loop diuretics, reduce their tubular secretion, and enha

180 with dapagliflozin significantly reduced new loop diuretic requirement over time.

181 One approach to overcome loop diuretic resistance is the addition of a thiazide-t

182 In patients with heart failure and loop diuretic resistance, dapagliflozin was not more eff

183 ot using a thiazide diuretic, or not using a loop diuretic, respectively.

184 Strategies to improve loop diuretic responsiveness include increasing diuretic

185 natriuresis, particularly when combined with loop diuretics, resulting in an improvement in blood vol

186 rs, beta-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors,

187 loride cotransporter gene family, including "loop" diuretic-sensitive Na-K-Cl cotransport and thiazid

188 Vasopressin receptor antagonists, urea, and loop diuretics serve this purpose, but received differen

189 Loop diuretic strategy of torsemide (n = 1431) or furose

190 s were randomly assigned in a 1:1 ratio to a loop diuretic strategy of torsemide or furosemide with i

191 ategorized by HF type and further divided by loop diuretic strategy.

192 gy of the K-Cl cotransporter is dominated by loop diuretics such as furosemide and bumetanide, molecu

193 c effect, a common liability associated with loop diuretics such as furosemide.

194 Diuretics (typically loop diuretics, such as furosemide or torsemide) should

195 Loop diuretics, such as furosemide, torsemide, and bumet

196 All three loop diuretics suppressed sound-triggered seizures in po

197 a putative drug target for a novel class of loop diuretic that would lower blood volume and pressure

198 Treatment with loop diuretics, the current cornerstone of decongestive

199 vaptan may allow for less intensification of loop diuretic therapy and a lower incidence of worsening

200 The addition of acetazolamide to loop diuretic therapy in patients with acute decompensat

201 atients otherwise resistant to high doses of loop diuretics, this strategy has not been subjected to

202 y (YDP) cohort, which used the NRPE to guide loop diuretic titration via a nurse-driven automated pro

203 ata suggest that administration of high-dose loop diuretics to patients with HF yields meaningful inc

204 otensin converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assess

205 cebo in addition to standardized intravenous loop diuretics (twice that of the oral home maintenance

206 toclopramide, domperidone, anticholinergics, loop diuretics, urologics, and ophthalmics.

207 Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks

208 use, as well as the effect of semaglutide on loop diuretic use and dose changes over the 52-week trea

209 short-term clinical benefits associated with loop diuretic use in HF.

210 s similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true

211 sis of heart failure may be often missed, or loop diuretic use is associated with other conditions wi

212 Mortality is more strongly associated with loop diuretic use than with a record of heart failure.

213 ar regardless of ejection fraction, previous loop diuretic use, and baseline health status.

214 tic groups, respectively (HR when the use of loop diuretics was compared with nonuse: 0.73; 95% CI: 0

215 Thiazide and loop diuretics were associated with higher risk of incid

216 Thiazide and loop diuretics were associated with increased gout risk,

217 ms, and scheduled treatment with intravenous loop diuretics were included.

218 tion, combination aldosterone antagonist and loop diuretics were more likely to resolve ascites (76%

219 Loop diuretics were used significantly more frequently b

220 he NRPE to predict 6-h sodium output after a loop diuretic, which was defined as poor (<50 mmol), sub

221 circulating blood decreases with the use of loop diuretics, which might result in less immediate tra

222 ith reduced ejection fraction taking regular loop diuretic who were randomized to empagliflozin 25 mg

223 1.3)], substantially higher for those taking loop diuretics with no record of heart failure [40%; adj

224 ma (0.73, 0.58-0.91); or an ACE inhibitor or loop diuretic without appropriate monitoring (0.51, 0.34

225 Many patients are prescribed loop diuretics without a diagnostic record of heart fail

226 cardiovascular disease, many are prescribed loop diuretics without a recorded diagnosis of heart fai